Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
Kevin Winthrop, Séverine Vermeire, Millie D. Long, et al.
Inflammatory Bowel Diseases (2022) Vol. 29, Iss. 1, pp. 85-96
Open Access | Times Cited: 19

Showing 19 citing articles:

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
William J. Sandborn, Geert R. D’Haens, Bruce E. Sands, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 3, pp. 338-351
Open Access | Times Cited: 58
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice
Rupa Banerjee, Vishal Sharma, Rajendra Patel, et al.
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 22-35
Closed Access | Times Cited: 7
REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis
Christopher Ma, Remo Panaccione, Yasi Xiao, et al.
The American Journal of Gastroenterology (2022) Vol. 118, Iss. 5, pp. 861-871
Open Access | Times Cited: 28
Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study
Hyuk Yoon, Byong Duk Ye, Sang‐Bum Kang, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Research advancements and perspectives of inflammatory bowel disease: A comprehensive review
JingShan Bai, Ying Wang, Fuhao Li, et al.
Science Progress (2024) Vol. 107, Iss. 2
Open Access | Times Cited: 3
Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
Hiromichi Shimizu, Yuko Aonuma, Shuji Hibiya, et al.
Intestinal Research (2024) Vol. 22, Iss. 3, pp. 369-377
Open Access | Times Cited: 2
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
Antonio Tursi, Giammarco Mocci, Linda Cingolani, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 14, pp. 1649-1656
Closed Access | Times Cited: 6
Emerging oral drug options for ulcerative colitis
Silvia Salvatori, Benedetto Neri, Irene Marafini, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 3, pp. 191-201
Closed Access | Times Cited: 5
Neutrophil-lymphocyte ratio: an independent predictor of the herpes zoster risk in rheumatoid arthritis patients treated with tofacitinib
Pengcheng Liu, Min Zhang, Yueqin Zhang, et al.
Aktuelle Rheumatologie (2024)
Closed Access | Times Cited: 1
Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators
Yu Kyung Jun, Hyuk Yoon
Korean Journal of Gastroenterology (2024) Vol. 84, Iss. 2, pp. 51-64
Open Access | Times Cited: 1
Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease
Walter Fries, Giorgio Basile, Federica Bellone, et al.
Cells (2023) Vol. 12, Iss. 13, pp. 1722-1722
Open Access | Times Cited: 3
Efficacy and Safety of Biological Therapies and Jak Inhibitors in Older Patients with Inflammatory Bowel Disease
Walter Fries, Giorgio Basile, Federica Bellone, et al.
(2023)
Open Access | Times Cited: 2
Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
Hans Herfarth, Anita Afzali, Monika Fischer, et al.
Clinical and Translational Gastroenterology (2023) Vol. 15, Iss. 3, pp. e00669-e00669
Open Access | Times Cited: 1
Incidencia de herpes zóster en pacientes con enfermedad inflamatoria intestinal: estudio observacional y retrospectivo en dos hospitales españoles de tercer nivel
Anna Calm, Margalida Calafat, Carlos González‐Muñoza, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 6, pp. 598-604
Closed Access
Incidence of herpes zoster in patients with inflammatory bowel disease
Anna Calm, Margalida Calafat, Carlos González‐Muñoza, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 6, pp. 598-604
Closed Access
Patients’ Preference on Advanced Therapy and Follow-Up Procedure for Inflammatory Bowel Disease in Japan: A Web-Based 3A Survey
Toshifumi Morishita, Shunichi Yanai, Yosuke Toya, et al.
Inflammatory Intestinal Diseases (2024) Vol. 9, Iss. 1, pp. 174-183
Open Access
Treatment Related Adverse Events and Monitoring of Patients Receiving Biologic or Small Molecule Therapy for Inflammatory Bowel Disease
Michael G. Stewart
Canadian IBD Today (2024)
Closed Access
Impfempfehlungen bei Immunsupprimierten
Selma Tobudic
rheuma plus (2024)
Open Access
Page 1

Scroll to top